EL (The Estee Lauder Companies Inc. Class A)
Insider Trading Activity
Every open-market purchase and sale reported by EL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-22 | BARRY S STERNLICHT | Director | A | — | — |
| 2026-07-22 | PAUL J FRIBOURG | Director | A | — | — |
| 2026-07-22 | Eric Louis Zinterhofer | Director | A | — | — |
| 2026-06-16 | Annabelle Yu Long | Director | A | — | — |
| 2026-06-16 | PAUL J FRIBOURG | Director | A | — | — |
| 2026-06-16 | Dana Strong | Director | A | — | — |
| 2026-06-16 | BARRY S STERNLICHT | Director | A | — | — |
| 2026-06-16 | Arturo Nunez | Director | A | — | — |
| 2026-06-16 | GARY M LAUDER | Director | A | — | — |
| 2026-06-16 | RICHARD F ZANNINO | Director | A | — | — |
| 2026-06-16 | CHARLENE BARSHEFSKY | Director | A | — | — |
| 2026-06-16 | Eric Louis Zinterhofer | Director | A | — | — |
| 2026-06-16 | JANE LAUDER | Director | A | — | — |
| 2026-06-16 | Jennifer Hyman | Director | A | — | — |
| 2026-06-16 | William P Lauder | Director | A | — | — |
| 2026-06-16 | Jennifer Tejada | Director | A | — | — |
| 2026-05-18 | BARRY S STERNLICHT | Director | A | — | — |
| 2026-05-18 | Eric Louis Zinterhofer | Director | A | — | — |
| 2026-05-18 | PAUL J FRIBOURG | Director | A | — | — |
| 2026-04-10 | RONALD S LAUDER | Chairman, Clinique Labs, LLC | G | — | — |
| 2026-04-10 | AERIN LAUDER | 10%+ Owner | G | — | — |
| 2026-03-17 | Dana Strong | Director | A | — | — |
| 2026-03-17 | Jennifer Tejada | Director | A | — | — |
| 2026-03-17 | RICHARD F ZANNINO | Director | A | — | — |
| 2026-03-17 | CHARLENE BARSHEFSKY | Director | A | — | — |
| 2026-03-17 | Jennifer Hyman | Director | A | — | — |
| 2026-03-17 | GARY M LAUDER | Director | A | — | — |
| 2026-03-17 | JANE LAUDER | Director | A | — | — |
| 2026-03-17 | Arturo Nunez | Director | A | — | — |
| 2026-03-17 | PAUL J FRIBOURG | Director | A | — | — |
| 2026-03-17 | Eric Louis Zinterhofer | Director | A | — | — |
| 2026-03-17 | Annabelle Yu Long | Director | A | — | — |
| 2026-03-17 | William P Lauder | Director | A | — | — |
| 2026-03-17 | BARRY S STERNLICHT | Director | A | — | — |
| 2026-03-02 | Hendrik Rene Lammers | EVP & CR&IO | A | — | — |
| 2026-03-02 | Akhil Shrivastava | Exec VP & CFO | MIXED | — | — |
| 2026-03-02 | Faverie Stephane de la | President and CEO | MIXED | — | — |
| 2026-03-02 | Eric Louis Zinterhofer | Director | A | — | — |
| 2026-03-02 | BARRY S STERNLICHT | Director | A | — | — |
| 2026-03-02 | PAUL J FRIBOURG | Director | A | — | — |
| 2025-12-16 | William P Lauder | Director | A | — | — |
| 2025-12-16 | JANE LAUDER | Director | A | — | — |
| 2025-12-16 | Eric Louis Zinterhofer | Director | A | — | — |
| 2025-12-16 | RICHARD F ZANNINO | Director | A | — | — |
| 2025-12-16 | Annabelle Yu Long | Director | A | — | — |
| 2025-12-16 | Arturo Nunez | Director | A | — | — |
| 2025-12-16 | Jennifer Tejada | Director | A | — | — |
| 2025-12-16 | GARY M LAUDER | Director | A | — | — |
| 2025-12-16 | Jennifer Hyman | Director | A | — | — |
| 2025-12-16 | Dana Strong | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Senior Corporate Vice Presiden | 6,153,604 | — |
| — | Director | 774,124 | — |
| — | Chairman, Clinique Labs, LLC | 706,364 | — |
| — | Director | 523,700 | — |
| — | President and CEO | 295,838 | — |
| — | Chairman Emeritus | 281,638 | — |
| — | 10%+ Owner | 184,293 | — |
| — | Group President, International | 181,288 | — |
| — | Director | 169,223 | — |
| — | EVP - Global Supply Chain | 93,383 | — |
| — | 10%+ Owner | 74,828 | — |
| — | Exec. V.P. - CFO | 73,390 | — |
| — | 10%+ Owner | 72,365 | — |
| — | Chief Operating Officer | 70,286 | — |
| — | 10%+ Owner | 69,353 | — |
| — | Director | 58,763 | — |
| — | EVP for Global Research & Dev. | 53,346 | — |
| — | EVP & CFO | 47,248 | — |
| — | Director | 46,812 | — |
| — | EVP - Global Human Resources | 39,431 | — |
| — | Director | 27,773 | — |
| — | Exec VP & CBO | 27,385 | — |
| — | President and CEO | 20,963 | — |
| — | Vice Chairman | 19,582 | — |
| — | Group President | 16,634 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the EL quote page; the site-wide leaderboard is on the insider transactions hub.